177Lu-PSMA: Single Time-Point Dosimetry Tied to Treatment Response in mCRPC

Scott Tagawa, MD, and Valentina Marulanda Corzo, MD, of Weill Cornell Medicine, discuss their work on a study presented at the SNMMI 2025 Annual Meeting that examined the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted radionuclide therapy in patients with mCRPC.

Dr. Marulanda Corzo describes the two different time points that were studied, as well as how future research should be focused on precision medicine and personalized therapy.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Conference Coverage

Live meeting highlights

Loïc Djaileb, MD, PhDRLT | July 21, 2025
Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Valentina Marulanda Corzo, MDRLT | July 18, 2025
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Nadine Mallak, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Brittany Miles, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.